Target
Serine/threonine-protein kinase PLK2
Ligand
BDBM50436735
Substrate
n/a
Meas. Tech.
ChEMBL_971578 (CHEMBL2406852)
IC50
21±n/a nM
Citation
 Bowers, STruong, APYe, MAubele, DLSealy, JMNeitz, RJHom, RKChan, WDappen, MSGalemmo, RAKonradi, AWSham, HLZhu, YLBeroza, PTonn, GZhang, HHoffman, JMotter, RFauss, DTanaka, PBova, MPRen, ZTam, DRuslim, LBaker, JPandya, DDiep, LFitzgerald, KArtis, DRAnderson, JPBergeron, M Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors. Bioorg Med Chem Lett 23:2743-9 (2013) [PubMed]  Article 
Target
Name:
Serine/threonine-protein kinase PLK2
Synonyms:
PLK2 | PLK2_HUMAN | Polo-Like Kinase 2 | SNK | Serine/threonine-protein kinase PLK2 | Serine/threonine-protein kinase SNK | Serum-inducible kinase
Type:
Serine/threonine-protein kinase
Mol. Mass.:
78259.87
Organism:
Homo sapiens (Human)
Description:
Full-length human PLK2 was expressed as GST-fusion protein using baculovirus expression system. GST-PLK2 was purified by using glutathione sepharose chromatography.
Residue:
685
Sequence:
MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHHHHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAKPHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEPEVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTICGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMPSSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPAKNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEELQPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLRGCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPDKKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRLYLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTLLMSGCSSELKNRMEYALNMLLQRCN
  
Inhibitor
Name:
BDBM50436735
Synonyms:
CHEMBL2402080
Type:
Small organic molecule
Emp. Form.:
C22H21FN8O
Mol. Mass.:
432.4535
SMILES:
CC[C@H]1N(c2cnn(C)c2)c2nc(ncc2N(C)C1=O)-n1ccnc1-c1ccc(F)cc1 |r|
Structure:
Search PDB for entries with ligand similarity: